Senolytics

Drugs that hunt down and kill the 'zombie' cells that drive aging.

As tissues age they accumulate senescent cells — cells that have stopped dividing but refuse to die, leaking inflammatory signals (the SASP) that poison their neighbors. Senolytics selectively trigger death in these cells while sparing healthy ones.

The clinical proof point is in the eye: clearing senescent cells in the retina has produced durable vision gains rivalling standard injections. Newer programs chase wider therapeutic windows by hitting targets like USP7 instead of first-generation Bcl-2/Bcl-xL survival proteins.

How it works in depth

As cells age or sustain damage, some stop dividing yet refuse to die. These senescent cells accumulate in tissues and secrete a toxic cocktail of inflammatory signals known as the senescence-associated secretory phenotype (SASP), which damages neighboring cells and drives chronic, low-grade inflammation linked to aging and many age-related diseases. Senescent cells survive by upregulating pro-survival 'anti-apoptotic' pathways. Senolytics exploit this dependency: they transiently block those survival pathways so the senescent cells trip their own self-destruct (apoptosis) program, while healthy cells are largely spared. The first-described combination, dasatinib plus quercetin (D+Q), hits multiple survival nodes; newer drugs target single proteins such as BCL-xL or modulate GPX4. Because the cells are cleared rather than continuously suppressed, senolytics are typically dosed intermittently ('hit-and-run') rather than daily.

Where the field is in 2025-2026

The field is still proving itself. The first-in-human senolytic study, an open-label Mayo Clinic pilot (n=14) led by researchers including James Kirkland and Tamar Tchkonia, used D+Q in idiopathic pulmonary fibrosis and showed feasibility and improved physical function, but it was small and uncontrolled. A separate D+Q trial in diabetic kidney disease reported reduced senescent-cell burden. Numerous academic D+Q trials (e.g., in older adults with serious mental illness) remain ongoing as of 2025-2026. The central debate: whether reducing senescent-cell markers translates into durable clinical benefit, and how to dose without off-target toxicity. Results so far are encouraging but preliminary, and no senolytic is FDA-approved.

Leading programs & players

UNITY Biotechnology has the most advanced asset, UBX1325 (foselutoclax), a BCL-xL inhibitor for retinal disease. Its Phase 2 BEHOLD study in diabetic macular edema reported best-corrected visual acuity gains, and the Phase 2b ASPIRE head-to-head versus aflibercept (reported May 2025, ~52 patients) found foselutoclax noninferior at 8 of 9 timepoints through 36 weeks but it reportedly missed the primary noninferiority endpoint. Rubedo Life Sciences advanced RLS-1496, described as a first-in-class topical GPX4 modulator, into a Phase 1 trial for plaque psoriasis and skin conditions, reporting early safety and signs of activity. Academic programs at Mayo Clinic and elsewhere continue to anchor the D+Q work. Market analysts project strong growth for senolytics and anti-aging pharmaceuticals through the early 2030s, though commercial reality hinges on the Phase 2/3 readouts expected across 2025-2027.

FAQ

What are senolytics in simple terms?

Drugs designed to selectively kill 'senescent' cells, damaged old cells that stop dividing but won't die and instead leak inflammatory signals that accelerate aging and age-related disease.

Are senolytics FDA approved?

No. As of 2026 no senolytic is approved. The most studied combination, dasatinib plus quercetin, is investigational for this use, and assets like UNITY's foselutoclax (UBX1325) remain in clinical trials.

What is dasatinib and quercetin (D+Q)?

D+Q is the original senolytic combo: dasatinib is an approved leukemia drug and quercetin is a plant flavonoid. Together they block multiple survival pathways in senescent cells. It is usually given intermittently in trials, not daily.

Which companies are leading senolytics development?

UNITY Biotechnology (UBX1325/foselutoclax, a BCL-xL inhibitor for eye disease) and Rubedo Life Sciences (RLS-1496, a topical GPX4 modulator) are notable, alongside academic D+Q programs led by groups such as Mayo Clinic.

Companies working on Senolytics

Explore the interactive landscapes →